Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | FABP2 | P12104 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1154123 | 0.90 | DNMT3A (0.66) | ALDH1A1KDM4EPKMDNMT3APPARA | |
| SCHEMBL3687774 | 0.86 | DNMT3A (0.69) | ALDH1A1KDM4EPKMDNMT3APPARA | |
| SCHEMBL1154562 | 0.86 | ALDH1A1 (0.56) | ALDH1A1KDM4EPKMDNMT3APPARA | |
| SCHEMBL1154185 | 0.85 | ALDH1A1 (0.51) | ALDH1A1KDM4EPKMDNMT3APPARA | |
| SCHEMBL1153879 | 0.84 | ALDH1A1 (0.58) | ALDH1A1KDM4EPKMDNMT3APPARA | |
| SCHEMBL1154495 | 0.84 | DNMT3A (0.63) | ALDH1A1KDM4EPKMDNMT3AHDAC1 | |
| SCHEMBL1153988 | 0.84 | DNMT3A (0.60) | ALDH1A1KDM4EPKMDNMT3APPARA | |
| SCHEMBL11683999 | 0.84 | PPARA (0.69) | ALDH1A1KDM4EPKMDNMT3APPARA | |
| SCHEMBL1154500 | 0.83 | DNMT3A (0.53) | DNMT3AHDAC1HDAC6LMNANLRP3 | |
| SCHEMBL1154220 | 0.82 | PPARA (0.55) | ALDH1A1KDM4EPKMDNMT3APPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299123-B2 | CCR10 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | claimed |
| EP-2215065-B1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-11 | — | — | EP | claimed |
| US-20110039851-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | US | claimed |
| EP-2215065-A1 | CCR10 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | claimed |
| WO-2009052078-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | claimed |
| US-8299123-B2 | CCR10 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299123-B2 | CCR10 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299123-B2 | CCR10 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| EP-2215065-B1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-11 | — | — | EP | disclosed |
| EP-2215065-B1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-11 | — | — | EP | disclosed |
| US-20110039851-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | US | disclosed |
| US-20110039851-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | US | disclosed |
| US-20110039851-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | US | disclosed |
| EP-2215065-A1 | CCR10 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009052078-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052078-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039851-A1 | CCR10 ANTAGONISTS | CCR10, CCR1, CCR4 | ALDH1A1 3036/4885KDM4E 3511/4885PKM 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.